The following is the eighth entry in a Q&A series highlighting selected Clinical Proteomic Tumor Analysis Consortium (CPTAC) researchers and their work. Join us as we discuss proteomic aspirations, the value of mentoring in science, and progress in multiple myeloma with Kiran Kumar Mangalaparthi, Ph.D., a Postdoctoral Researcher at Mayo Clinic in Rochester, Minnesota.…
COVID-19 is an emerging, rapidly evolving siituation.
What people with cancer should know: https://www.cancer.gov/coronavirus
Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers
Get the latest public health information from CDC: https://www.coronavirus.gov
Get the latest research information from NIH: https://www.nih.gov/coronavirus
News and Announcements
March 10, 2025
Data analysis in proteogenomics has taken a marked step forward with the introduction of a new bioinformatics platform, Multiomics2Targets. This platform, developed by CPTAC researchers at the Icahn School of Medicine at Mount Sinai and published in Cell Reports Methods, integrates transcriptomics, proteomics, and phosphoproteomics data to identify potential therapeutic targets and is capable of generating detailed reports automatically. A companion protocol article describing how to use the system was also recently published in STAR Protocols.